


Table 9. The inhibitory effect of compounds (26-30) on neutrophil superoxide formation (*in vitro*)



Inducer: fMLP (0.3 μ M)/ cytochalasin B (5 μ g/ml)

Animal: Rat (Sprague Dawley)


Inducer: PMA (3 nM)

No.	Conc. (μ M)	R ₂	R ₂ '	R ₄ ''	Superoxide Formation (nmol/10 ⁶ cells/30 min)			
					fMLP	% inhibition	PMA	% inhibition
	Control				2.45 \pm 0.21		7.34 \pm 0.26	
26	10	COOEt	F	Cl	2.63 \pm 0.37	-6.27 \pm 8.4	6.66 \pm 0.71	8.9 \pm 0.2
	30				2.48 \pm 0.37	-0.8 \pm 0.7	4.81 \pm 0.59*	34.4 \pm 7.6*
	Control				2.45 \pm 0.21		7.34 \pm 0.26	
27	10	COOEt	F	F	2.33 \pm 0.23	4.9 \pm 3.3	6.37 \pm 0.44	13.2 \pm 4.7
	30				2.22 \pm 0.30	9.9 \pm 7.7	5.48 \pm 0.63	25.3 \pm 7.9
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
28	10	H	Cl	F	4.08 \pm 0.21	4.7 \pm 3.6	7.63 \pm 0.61	8.4 \pm 2.2
	30				4.23 \pm 0.12	1.2 \pm 1.1	7.62 \pm 0.52	6.4 \pm 3.0
	Control				2.45 \pm 0.21		7.34 \pm 0.26	
29	10	H	F	OCH ₃	2.56 \pm 0.34	-4.7 \pm 7.0	6.06 \pm 0.22	17.1 \pm 5.7
	30				2.37 \pm 0.33	4.0 \pm 6.9	6.34 \pm 0.77	11.7 \pm 2.4
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
30	10	H	Cl	H	4.12 \pm 0.34	4.0 \pm 6.2	8.22 \pm 0.20	0.3 \pm 6.9
	30				4.28 \pm 0.14	0.2 \pm 1.8	7.95 \pm 0.17	3.5 \pm 7.1
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
TFP	1				--	--	6.02 \pm 0.13	27.6 \pm 4.2
	3				4.16 \pm 0.27	1.7 \pm 6.6	3.73 \pm 0.27**	55.4 \pm 9.4**
	5				3.17 \pm 0.09*	24.2 \pm 5.3*	--	--
	10				0.81 \pm 0.22**	79.5 \pm 4.2**	1.39 \pm 0.16**	83.3 \pm 5.8**
	IC ₅₀				6.6 \pm 0.2 μ M		2.7 \pm 0.6 μ M	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

Triperazine (TFP): positive control

Table 10. The inhibitory effect of compounds (31-37, 39-41) on neutrophil superoxide formation (*in vitro*)



Inducer: fMLP (0.3 μ M)/ cytochalasin B (5 μ g/ml)

Animal: Rat (Sprague Dawley)

Inducer: PMA (3 nM)


No.	Conc. (μ M)	R ₆	R ₂ '	R ₄ '	Superoxide Formation (nmol/10 ⁶ cells/30 min)			
					fMLP	% inhibition	PMA	% inhibition
31	Control				4.28 \pm 0.08		8.36 \pm 0.79	
	10	Cl	F	H	3.51 \pm 0.14	18.1 \pm 2.1	6.86 \pm 0.60	16.3 \pm 0.5
	30				3.19 \pm 0.09*	25.5 \pm 1.0*	7.87 \pm 0.68	5.6 \pm 2.9
32	Control				4.28 \pm 0.08		8.36 \pm 0.79	
	3	Cl	Cl	H	3.05 \pm 0.16*	27.4 \pm 6.2*	--	--
	10				1.80 \pm 0.03**	57.2 \pm 2.5**	6.90 \pm 0.38	16.5 \pm 6.3
	30				0.12 \pm 0.05**	97.0 \pm 1.3**	9.74 \pm 1.60	-15.0 \pm 9.7
	IC ₅₀				6.8 \pm 0.8 μ M			
33	Control				4.28 \pm 0.08		8.36 \pm 0.79	
	10	Cl	OCH ₃	H	3.04 \pm 0.27**	29.1 \pm 5.0**	7.62 \pm 0.75	7.6 \pm 0.6
	30				2.88 \pm 0.18**	32.7 \pm 3.5**	9.65 \pm 1.82	-13.4 \pm 2.7
34	Control				2.45 \pm 0.21		7.34 \pm 0.26	
	10	Cl	H	H	2.32 \pm 0.24	4.6 \pm 6.1	9.79 \pm 0.57	-34.5 \pm 4.4
	30				2.39 \pm 0.16	1.0 \pm 5.3	9.40 \pm 0.76	-28.9 \pm 6.4
35	Control				4.28 \pm 0.08		8.36 \pm 0.79	
	10	F	F	H	3.19 \pm 0.12*	25.5 \pm 1.5*	7.16 \pm 0.13	12.9 \pm 7.6
	30				2.97 \pm 0.18**	30.7 \pm 3.0**	6.38 \pm 0.86	23.9 \pm 5.2
36	Control				4.28 \pm 0.08		8.36 \pm 0.79	
	3	F	Cl	H	3.33 \pm 0.60	22.8 \pm 8.8	--	--
	10				2.58 \pm 0.30*	39.3 \pm 5.6*	7.26 \pm 0.44	10.6 \pm 3.5
	30				1.51 \pm 0.15**	64.3 \pm 3.5**	7.05 \pm 0.78	15.4 \pm 6.0
	IC ₅₀				13.8 \pm 1.0 μ M			
37	Control				4.28 \pm 0.08		8.36 \pm 0.79	
	10	F	OCH ₃	H	3.47 \pm 0.24	18.9 \pm 4.5	6.09 \pm 0.17	26.1 \pm 5.7

	30				3.34 ±0.22	22.0 ±5.2	5.77 ±0.16	29.4 ±8.1
	Control				4.28 ±0.08		8.36 ±0.79	
39	10	OCH ₃	F	H	3.57 ±0.23	16.7 ±4.2	6.07 ±0.34	25.3 ±0.8
	30				3.13 ±0.30*	27.0 ±5.9*	7.55 ±0.20	8.5 ±6.2
	Control				4.28 ±0.08		8.36 ±0.79	
40	3	OCH ₃	Cl	H	3.78 ±0.36	11.5 ±2.6	--	--
	10				2.88 ±0.26**	32.4 ±1.6**	6.21 ±0.41	25.1 ±3.8
	30				1.43 ±0.15**	66.3 ±1.6**	7.16 ±0.69	14.0 ±5.6
	IC₅₀				16.7 ±1.0 μM			
	Control				2.45 ±0.21		7.34 ±0.26	
41	10	OCH ₃	H	F	2.08 ±0.25	14.6 ±2.2	10.2 ±0.35	-39.8 ±6.3
	30				2.13 ±0.19	12.1 ±2.9	10.2 ±0.62	-39.3 ±2.2
	Control				4.28 ±0.08		8.36 ±0.79	
TFP	1				--	--	6.02 ±0.13	27.6 ±4.2
	3				4.16 ±0.27	1.7 ±6.6	3.73 ±0.27**	55.4 ±9.4**
	5				3.17 ±0.09*	24.2 ±5.3*	--	--
	10				0.81 ±0.22**	79.5 ±4.2**	1.39 ±0.16**	83.3 ±5.8**
	IC₅₀				6.6 ±0.2 μM		2.7 ±0.6 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

Triperazine (TFP): positive control

Table 11. The inhibitory effect of compounds (43, 44) on neutrophil superoxide formation (*in vitro*)



Inducer: fMLP (0.3 μ M)/ cytochalasin B (5 μ g/ml)

Animal: Rat (Sprague Dawley)


Inducer: PMA (3 nM)

No.	Conc. (μ M)	R ₆	R ₂ '	Superoxide Formation (nmol/10 ⁶ cells/30 min)			
				fMLP	% inhibition	PMA	% inhibition
Control				4.28 \pm 0.08		8.36 \pm 0.79	
43	10	F	F	3.21 \pm 0.19*	25.0 \pm 4.4*	9.60 \pm 0.85	-14.9 \pm 1.9
	30			3.37 \pm 0.22	21.4 \pm 4.2	9.76 \pm 0.90	-16.7 \pm 2.1
44	10	OCH ₃	Cl	2.88 \pm 0.15**	32.7 \pm 2.3**	8.81 \pm 0.11	-7.23 \pm 0.9
	30			2.81 \pm 0.11**	34.2 \pm 2.8**	10.0 \pm 0.62	-21.1 \pm 3.9
TFP	1			--	--	6.02 \pm 0.13	27.6 \pm 4.2
	3			4.16 \pm 0.27	1.7 \pm 6.6	3.73 \pm 0.27**	55.4 \pm 9.4**
	5			3.17 \pm 0.09*	24.2 \pm 5.3*	--	--
	10			0.81 \pm 0.22**	79.5 \pm 4.2**	1.39 \pm 0.16**	83.3 \pm 5.8**
IC₅₀				6.6 \pm 0.2 μM		2.7 \pm 0.6 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

Triperazine (TFP): positive control

Table 12. The inhibitory effect of compounds (45-51, 53-55) on neutrophil superoxide formation (*in vitro*)



Inducer: fMLP (0.3 μ M)/ cytochalasin B (5 μ g/ml)

Animal: Rat (Sprague Dawley)

Inducer: PMA (3 nM)


No.	Conc. (μ M)	R ₆	R ₂ '	R ₄ '	Superoxide Formation (nmol/10 ⁶ cells/30 min)			
					fMLP	% inhibition	PMA	% inhibition
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
45	10	Cl	F	H	3.42 \pm 0.20	20.3 \pm 3.3	6.52 \pm 0.10	20.4 \pm 8.2
	30				2.59 \pm 0.22**	39.6 \pm 4.2**	6.58 \pm 0.33	20.2 \pm 6.4
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
46	3	Cl	Cl	H	3.61 \pm 0.16	14.7 \pm 4.3	--	--
	10				2.77 \pm 0.39**	35.0 \pm 7.4**	7.14 \pm 0.42	13.8 \pm 4.5
	30				2.10 \pm 0.16**	50.6 \pm 0.5**	7.47 \pm 0.74	10.6 \pm 0.4
	IC ₅₀				24.9 \pm 3.2 μ M			
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
47	10	Cl	OCH ₃	H	3.26 \pm 0.20*	23.7 \pm 4.5*	6.34 \pm 0.23	23.2 \pm 4.4
	30				3.05 \pm 0.17**	28.8 \pm 2.8**	7.30 \pm 0.55	10.4 \pm 2.4
	Control				2.45 \pm 0.21		7.34 \pm 0.26	
48	10	Cl	H	H	2.00 \pm 0.22	17.7 \pm 3.6	7.17 \pm 0.99	1.5 \pm 3.0
	30				1.94 \pm 0.23	19.4 \pm 8.4	6.71 \pm 0.81	8.5 \pm 6.4
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
49	10	F	F	H	3.54 \pm 0.22	17.5 \pm 3.6	7.53 \pm 0.56	8.6 \pm 9.1
	30				3.24 \pm 0.21*	24.4 \pm 3.9*	6.91 \pm 1.06	17.8 \pm 6.7
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
50	10	F	Cl	H	3.40 \pm 0.16	20.5 \pm 3.3	7.43 \pm 0.33	8.8 \pm 2.3
	30				2.96 \pm 0.24**	31.0 \pm 4.4**	6.58 \pm 0.15	19.8 \pm 7.7
	Control				4.28 \pm 0.08		8.36 \pm 0.79	
51	10	F	OCH ₃	H	3.20 \pm 0.16*	25.3 \pm 2.5*	6.53 \pm 0.61	21.7 \pm 2.3
	30				3.11 \pm 0.22*	27.5 \pm 4.0*	6.48 \pm 0.39	21.5 \pm 6.1
	Control				4.28 \pm 0.08		8.36 \pm 0.79	

53	10	OCH ₃	F	H	3.26 ±0.28*	24.0 ±5.2*	6.47 ±0.32	21.9 ±3.5
	30				2.91 ±0.08**	32.0 ±2.0**	6.47 ±0.68	22.6 ±2.0
	Control				4.28 ±0.08		8.36 ±0.79	
54	10	OCH ₃	Cl	H	3.19 ±0.06*	25.5 ±0.8*	7.80 ±0.80	6.3 ±6.9
	30				2.42 ±0.11**	43.3 ±2.6**	6.73 ±0.27	17.5 ±0.7
	Control				2.45 ±0.21		7.34 ±0.26	
55	10	OCH ₃	H	F	2.03 ±0.29	17.3 ±1.1	6.72 ±0.79	7.9 ±9.1
	30				1.99 ±0.21	18.4 ±2.5	5.28 ±0.94	28.3 ±8.3
	Control				4.28 ±0.08		8.36 ±0.79	
TFP	1				--	--	6.02 ±0.13	27.6 ±4.2
	3				4.16 ±0.27	1.7 ±6.6	3.73 ±0.27**	55.4 ±9.4**
	5				3.17 ±0.09*	24.2 ±5.3*	-	-
	10				0.81 ±0.22**	79.5 ±4.2**	1.39 ±0.16**	83.3 ±5.8**
	IC₅₀					6.6 ±0.2 μM		2.7 ±0.6 μM

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

Triperazine (TFP): positive control

Table 13. The inhibitory effect of compounds (26-30) on neutrophil degranulation (*in vitro*)



Animal: Rat (Sprague Dawley)


Inducer: fMLP (1 μ M)/ cytochalasin B (5 μ g/ml)

No.	Conc. (μ M)	R ₂	R ₂ '	R ₄ ''	Percent Release			
					-Glucuronidase	% inhibition	Lysozyme	% inhibition
26	Control				31.2 \pm 2.6		70.9 \pm 4.3	
	10	COOEt	F	Cl	28.0 \pm 3.4	10.9 \pm 4.4	66.3 \pm 4.7	6.5 \pm 1.6
	30				25.7 \pm 3.0	17.9 \pm 5.2	61.6 \pm 5.1	13.3 \pm 2.6
27	Control				31.2 \pm 2.6		70.9 \pm 4.3	
	10	COOEt	F	F	29.8 \pm 2.0	4.2 \pm 1.8	66.7 \pm 3.3	5.7 \pm 3.0
	30				25.9 \pm 2.4	17.1 \pm 1.0	59.2 \pm 5.1	16.6 \pm 2.6
28	Control				35.1 \pm 1.0		49.6 \pm 2.4	
	10	H	Cl	F	35.6 \pm 1.6	-1.1 \pm 4.5	56.2 \pm 4.5	-13.0 \pm 5.9
	30				36.7 \pm 1.7	-4.2 \pm 4.7	55.7 \pm 3.9	-12.3 \pm 6.9
29	Control				31.2 \pm 2.6		70.9 \pm 4.3	
	10	H	F	OCH ₃	32.4 \pm 2.4	-3.9 \pm 4.3	76.2 \pm 3.1	-7.7 \pm 2.5
	30				38.5 \pm 3.2	-23.6 \pm 5.0	85.9 \pm 7.1	-21.2 \pm 6.7
30	Control				35.1 \pm 1.0		49.6 \pm 2.4	
	10	H	Cl	H	36.2 \pm 1.8	-3.1 \pm 5.5	64.7 \pm 4.5	-30.2 \pm 4.4
	30				36.9 \pm 2.9	-5.0 \pm 7.5	62.9 \pm 2.8	-26.9 \pm 2.6
TFP	Control				35.1 \pm 1.0		49.6 \pm 2.4	
	3				36.1 \pm 0.6	-3.7 \pm 2.9	57.5 \pm 0.4	-17.8 \pm 2.8
	10				15.5 \pm 0.4**	55.2 \pm 0.2**	31.5 \pm 4.3*	35.3 \pm 6.3*
	30				8.0 \pm 1.1**	76.7 \pm 4.0**	10.2 \pm 2.6**	79.2 \pm 3.8**
IC₅₀					10.6 \pm 0.9 μM		13.2 \pm 0.7 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3

Trifluoperazine (TFP): positive control

Table 14. The inhibitory effect of compounds (31-37, 39-41) on neutrophil degranulation (*in vitro*)



Animal: Rat (Sprague Dawley)

Inducer: fMLP (1 μ M)/ cytochalasin B (5 μ g/ml)


No.	Conc. (μ M)	R ₆	R ₂ '	R ₄ '	Percent Release			
					-Glucuronidase	% inhibition	Lysozyme	% inhibition
	Control				35.1 \pm 0		49.6 \pm 4	
31	10	Cl	F	H	28.3 \pm 4	19.7 \pm 8.3	38.3 \pm 5.1	22.3 \pm 0.9
	30				25.1 \pm 4	28.9 \pm 8.3	36.1 \pm 6.6	27.1 \pm 2.8
	Control				35.1 \pm 0		49.6 \pm 4	
32	10	Cl	Cl	H	25.9 \pm 7	26.4 \pm 4.4	41.6 \pm 6	15.9 \pm 6
	30				17.7 \pm 3.3**	49.6 \pm 9.4**	30.8 \pm 3*	37.9 \pm 2.5*
	Control				35.1 \pm 0		49.6 \pm 4	
33	10	Cl	OCH ₃	H	30.4 \pm 4	13.2 \pm 4.6	50.3 \pm 8	-1.0 \pm 0
	30				30.8 \pm 0.9	12.3 \pm 3.4	46.2 \pm 3.6	7.1 \pm 3.1
	Control				31.2 \pm 6		70.9 \pm 3	
34	10	Cl	H	H	30.4 \pm 0	2.5 \pm 4.9	79.1 \pm 7	-12.0 \pm 3.4
	30				28.6 \pm 8	8.4 \pm 5.6	74.5 \pm 3.2	-5.4 \pm 3.1
	Control				35.1 \pm 0		49.6 \pm 4	
35	10	F	F	H	30.7 \pm 0.4	12.5 \pm 1.2	51.2 \pm 3.6	-2.9 \pm 2.9
	30				30.0 \pm 0.7	14.5 \pm 2.1	46.5 \pm 4.1	6.5 \pm 4.4
	Control				35.1 \pm 0		49.6 \pm 4	
36	10	F	Cl	H	28.0 \pm 0.9	20.2 \pm 0.3	44.8 \pm 6.1	9.1 \pm 2.5
	30				20.2 \pm 4.0**	42.7 \pm 0.9**	45.1 \pm 6.7	6.7 \pm 7.6
	Control				35.1 \pm 0		49.6 \pm 4	
37	10	F	OCH ₃	H	31.4 \pm 8	10.7 \pm 3.0	54.8 \pm 7	-10.5 \pm 4.5
	30				32.1 \pm 1.1	8.7 \pm 2.8	54.4 \pm 3	-9.7 \pm 7
	Control				35.1 \pm 0		49.6 \pm 4	
39	10	OCH ₃	F	H	30.5 \pm 2	13.2 \pm 2.6	55.0 \pm 3.9	-10.6 \pm 4.1
	30				29.9 \pm 0.9	14.8 \pm 1.3	53.9 \pm 3.9	-8.2 \pm 9
	Control				35.1 \pm 0		49.6 \pm 4	

40	10	OCH ₃	Cl	H	32.2 ±1.4	8.4 ±3.7	54.2 ±2.2	-9.3 ±2.9
	30				26.8 ±0.5	23.5 ±0.5	46.5 ±3.0	6.4 ±3.9
	Control				31.2 ±2.6		70.9 ±4.3	
41	10	OCH ₃	H	F	38.7 ±3.1	-24.0 ±2.6	78.5 ±4.0	-11.0 ±2.5
	30				38.5 ±3.2	-23.6 ±5.0	85.9 ±7.1	-21.2 ±6.7
	Control				35.1 ±1.0		49.6 ±2.4	
TFP	3				36.1 ±0.6	-3.7 ±2.9	57.5 ±0.4	-17.8 ±2.8
	10				15.5 ±0.4**	55.2 ±0.2**	31.5 ±4.3*	35.3 ±6.3*
	30				8.0 ±1.1**	76.7 ±4.0**	10.2 ±2.6**	79.2 ±3.8**
	IC₅₀				10.6 ±0.9 μM		13.2 ±0.7 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3

Trifluoperazine (TFP): positive control

Table 15. The inhibitory effect of compounds (43, 44) on neutrophil degranulation (*in vitro*)



Animal: Rat (Sprague Dawley)


Inducer: fMLP (1 μ M)/ cytochalasin B (5 μ g/ml)

No.	Conc. (μ M)	R ₆	R ₂ '	Percent Release			
				-Glucuronidase	% inhibition	Lysozyme	% inhibition
	Control			35.1 \pm 1.0		49.6 \pm 2.4	
43	10	F	F	28.7 \pm 1.1	18.2 \pm 2.3	52.5 \pm 5.0	-5.3 \pm 5.3
	30			31.0 \pm 0.7	11.6 \pm 2.6	54.0 \pm 3.5	-8.7 \pm 2.1
44	10	OCH ₃	Cl	26.7 \pm 1.6	24.3 \pm 3.1	50.8 \pm 2.8	-2.4 \pm 2.5
	30			26.9 \pm 1.4	23.4 \pm 2.5	49.9 \pm 2.5	-0.7 \pm 2.1
TFP	3			36.1 \pm 0.6	-3.7 \pm 2.9	57.5 \pm 0.4	-17.8 \pm 2.8
	10			15.5 \pm 0.4**	55.2 \pm 0.2**	31.5 \pm 4.3*	35.3 \pm 6.3*
	30			8.0 \pm 1.1**	76.7 \pm 4.0**	10.2 \pm 2.6**	79.2 \pm 3.8**
	IC₅₀			10.6 \pm 0.9 μM		13.2 \pm 0.7 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3

Trifluoperazine (TFP): positive control

Table 16. The inhibitory effect of compounds (45-51, 53-55) on neutrophil degranulation (*in vitro*)



Animal: Rat (Sprague Dawley)

Inducer: fMLP (1 μ M)/ cytochalasin B (5 μ g/ml)

No.	Conc. (μ M)	R ₆	R ₂ '	R ₄ '	Percent Release			
					-Glucuronidase	% inhibition	Lysozyme	% inhibition
	Control				35.1 \pm 0		73.1 \pm 8	
45	10	Cl	F	H	31.4 \pm 2	10.4 \pm 3.4	47.9 \pm 3	3.2 \pm 3
	30				29.9 \pm 0.7	14.7 \pm 1.9	45.7 \pm 3	8.1 \pm 4
	Control				35.1 \pm 0		49.6 \pm 4	
46	10	Cl	Cl	H	30.7 \pm 4	12.6 \pm 3.7	47.5 \pm 9	4.2 \pm 6
	30				29.7 \pm 6	15.4 \pm 4.0	46.7 \pm 3	5.8 \pm 7
	Control				35.1 \pm 0		49.6 \pm 4	
47	10	Cl	OCH ₃	H	31.7 \pm 0	9.7 \pm 3.2	51.5 \pm 0	-3.4 \pm 5
	30				31.0 \pm 1	11.7 \pm 3.0	51.3 \pm 9	-3.3 \pm 5
	Control				31.2 \pm 6		70.9 \pm 3	
48	10	Cl	H	H	27.9 \pm 9	10.2 \pm 3	73.4 \pm 5	-3.9 \pm 5
	30				24.7 \pm 5	21.0 \pm 2.3	69.3 \pm 8	1.7 \pm 6
	Control				35.1 \pm 0		49.6 \pm 4	
49	10	F	F	H	31.8 \pm 2	9.5 \pm 2.5	54.6 \pm 3	-9.9 \pm 2
	30				31.7 \pm 2	9.8 \pm 1.3	51.0 \pm 9	-2.7 \pm 1
	Control				35.1 \pm 0		49.6 \pm 4	
50	10	F	Cl	H	32.0 \pm 6	8.9 \pm 4.3	53.5 \pm 6	-8.0 \pm 5
	30				30.5 \pm 3	13.1 \pm 4.5	51.1 \pm 3	-2.8 \pm 9
	Control				35.1 \pm 0		49.6 \pm 4	
51	10	F	OCH ₃	H	31.8 \pm 5	9.8 \pm 1.3	52.2 \pm 7	-5.3 \pm 7
	30				31.3 \pm 3	10.9 \pm 2.8	52.4 \pm 9	-5.6 \pm 3
	Control				35.1 \pm 0		49.6 \pm 4	
53	10	OCH ₃	F	H	31.1 \pm 2	11.4 \pm 0.9	55.7 \pm 9	-12.2 \pm 3
	30				30.0 \pm 0	14.6 \pm 0.7	54.5 \pm 8	-9.9 \pm 5
	Control				35.1 \pm 0		49.6 \pm 4	

54	10	OCH ₃	Cl	H	32.6 ± 1.4	7.2 ± 3.1	55.9 ± 2.2	-12.8 ± 1.5
	30				33.0 ± 1.4	5.9 ± 2.8	55.2 ± 2.3	-11.2 ± 1.7
	Control				31.2 ± 2.6		70.9 ± 4.3	
55	10	OCH ₃	H	F	38.1 ± 2.1	-22.6 ± 3.8	74.4 ± 3.6	-5.2 ± 4.2
	30				3.5 ± 1.8	-7.9 ± 4.0	68.2 ± 3.9	3.4 ± 4.3
	Control				35.1 ± 1.0		49.6 ± 2.4	
TFP	3				36.1 ± 0.6	-3.7 ± 2.9	57.5 ± 0.4	-17.8 ± 2.8
	10				15.5 ± 0.4**	55.2 ± 0.2**	31.5 ± 4.3*	35.3 ± 6.3*
	30				8.0 ± 1.1**	76.7 ± 4.0**	10.2 ± 2.6**	79.2 ± 3.8**
	IC₅₀				10.6 ± 0.9 μM		13.2 ± 0.7 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3

Trifluoperazine (TFP): positive control